Journals

Conferences

Open Access Articles- Top Results for Edaravone

Edaravone

</th></tr>
Edaravone
File:Edaravone.png
Systematic (IUPAC) name
5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one
Clinical data
  • (Prescription only)
Oral
Identifiers
89-25-8 7pxY
None
PubChem CID 4021
ChemSpider 3881 7pxY
UNII S798V6YJRP 7pxY
KEGG D01552 7pxY
ChEBI CHEBI:31530 7pxY
ChEMBL CHEMBL290916 7pxY
Synonyms MCI-186
Chemical data
Formula C10H10N2O
174.20 g/mol
 14pxY (what is this?)  (verify)

Edaravone (brand name Radicut) is a nootropic and neuroprotective agent used for the purpose of aiding neurological recovery following acute brain ischemia and subsequent cerebral infarction.[1] It acts as a potent antioxidant and strongly scavenges free radicals, protecting against oxidative stress and neuronal apoptosis.[2][3][4] It has been marketed solely in Japan by Mitsubishi Pharma since 2001.[1] and marketed in India by Edinburgh Pharmaceuticals by the brand name Arone

Edaravone has been shown to attenuate methamphetamine- and 6-OHDA-induced dopaminergic neurotoxicity in the striatum and substantia nigra, and does not affect methamphetamine-induced dopamine release or hyperthermia.[5][6] It has also been demonstrated to protect against MPTP-mediated dopaminergic neurotoxicity to the substantia nigra, though notably not to the striatum.[7][8][9]

References

  1. ^ a b Doherty, Annette M. (2002). Annual Reports in Medicinal Chemistry, Volume 37 (Annual Reports in Medicinal Chemistry). Boston: Academic Press. ISBN 0-12-040537-7. 
  2. ^ Watanabe T, Tanaka M, Watanabe K, Takamatsu Y, Tobe A (March 2004). "[Research and development of the free radical scavenger edaravone as a neuroprotectant]". Yakugaku Zasshi (in Japanese) 124 (3): 99–111. PMID 15049127. doi:10.1248/yakushi.124.99. 
  3. ^ Higashi Y, Jitsuiki D, Chayama K, Yoshizumi M (January 2006). "Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases". Recent Patents on Cardiovascular Drug Discovery 1 (1): 85–93. PMID 18221078. doi:10.2174/157489006775244191. 
  4. ^ Yoshida H, Yanai H, Namiki Y, Fukatsu-Sasaki K, Furutani N, Tada N (2006). "Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury". CNS Drug Reviews 12 (1): 9–20. PMID 16834755. doi:10.1111/j.1527-3458.2006.00009.x. 
  5. ^ Yuan WJ, Yasuhara T, Shingo T et al. (2008). "Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons". BMC Neuroscience 9: 75. PMC 2533664. PMID 18671880. doi:10.1186/1471-2202-9-75. 
  6. ^ Kawasaki T, Ishihara K, Ago Y et al. (August 2006). "Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum". European Journal of Pharmacology 542 (1-3): 92–9. PMID 16784740. doi:10.1016/j.ejphar.2006.05.012. 
  7. ^ Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T (July 2007). "Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum". The Journal of Pharmacology and Experimental Therapeutics 322 (1): 274–81. PMID 17429058. doi:10.1124/jpet.106.119206. 
  8. ^ Yokoyama H, Takagi S, Watanabe Y, Kato H, Araki T (June 2008). "Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice". Journal of Neural Transmission (Vienna, Austria : 1996) 115 (6): 831–42. PMID 18235988. doi:10.1007/s00702-008-0019-6. 
  9. ^ Yokoyama H, Yano R, Aoki E, Kato H, Araki T (September 2008). "Comparative pharmacological study of free radical scavenger, nitric oxide synthase inhibitor, nitric oxide synthase activator and cyclooxygenase inhibitor against MPTP neurotoxicity in mice". Metabolic Brain Disease 23 (3): 335–49. PMID 18648914. doi:10.1007/s11011-008-9096-3. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.